MDxHealth Reports Half Year 2022 Results
NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET
Read more:
MDxHealth Reports Half Year 2022 Results
Author Archives: admin
Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering
WALTHAM, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that it has issued an additional 1,725,000 shares of common stock at a public offering price of $23.50 per share, resulting in additional gross proceeds of approximately $40.5 million, pursuant to the exercise in full of the underwriters’ option to purchase additional shares of common stock in connection with the Company’s previously announced public offering of common stock and Series B Preferred Stock. After giving effect to the full exercise of the underwriters’ option to purchase additional shares of common stock, the total number of shares of common stock sold by Viridian in the underwritten public offering was 11,352,640 shares. In addition, approximately 1,872,360 shares of common stock are issuable upon conversion of the 28,084 shares of Series B Preferred Stock sold in the offering. The gross proceeds from the sale of shares of common stock and Series B Preferred Stock were approximately $311 million, before deducting underwriting discounts and commissions and other offering expenses payable by Viridian.
Here is the original post:
Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in…
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted expanded coverage for the use of Myriad’s BRACAnalysis® Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza®(olaparib).
Here is the original post:
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in...
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board
Here is the original post:
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
Kane Biotech Announces Second Quarter 2022 Financial Results
Significant Milestones Achieved Significant Milestones Achieved
See the rest here:
Kane Biotech Announces Second Quarter 2022 Financial Results
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU.
Originally posted here:
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited (“Takeda”). Following a review of its pipeline, Takeda informed Finch of its decision to terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.
Read the original:
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update
TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or "Blueberries"), is pleased to report its financial results for the quarter ended on June 30, 2022. Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All amounts are expressed in Canadian dollars, unless otherwise noted.
See the original post here:
Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA -- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA
Here is the original post:
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.
Read the original:
Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group